keyword
MENU ▼
Read by QxMD icon Read
search

Apligraf

keyword
https://www.readbyqxmd.com/read/27681811/a-comparative-analysis-of-skin-substitutes-used-in-the-management-of-diabetic-foot-ulcers
#1
M Martinson, N Martinson
OBJECTIVE: To compare the relative product cost and clinical outcomes of four skin substitutes used as adjunctive treatments for diabetic foot ulcers (DFUs). METHOD: Medicare claims data from 2011 to 2014 were used to identify beneficiaries with diabetes and foot ulcers. Patients treated with one of four types of skin substitute (Apligraf, Dermagraft, OASIS, and MatriStem) were identified. The skin substitutes were compared on episode length; amputation rate; skin substitute utilisation; and skin substitute costs...
October 2016: Journal of Wound Care
https://www.readbyqxmd.com/read/25786331/economic-outcomes-among-medicare-patients-receiving-bioengineered-cellular-technologies-for-treatment-of-diabetic-foot-ulcers
#2
J Bradford Rice, Urvi Desai, Ljubica Ristovska, Alice Kate G Cummings, Howard G Birnbaum, Michelle Skornicki, David J Margolis, Nathan B Parsons
OBJECTIVE: To assess the real-world medical services utilization and associated costs of Medicare patients with diabetic foot ulcers (DFUs) treated with Apligraf (bioengineered living cellular construct (BLCC)) or Dermagraft (human fibroblast-derived dermal substitute (HFDS)) compared with those receiving conventional care (CC). METHODS: DFU patients were selected from Medicare de-identified administrative claims using ICD-9-CM codes. The analysis followed an 'intent-to-treat' design, with cohorts assigned based on use of (1) BLCC, (2) HFDS, or (3) CC (i...
2015: Journal of Medical Economics
https://www.readbyqxmd.com/read/25543821/use-of-hbot-and-a-living-bilayer-skin-substitute-for-a-compromised-flap-with-chronic-steroid-use-a-case-report
#3
A L Pistorio, J Leslie, R B Gustavson, R C Baynosa
UNLABELLED: Wound healing in a degloving injury can be compromised due to mechanical compression, increased length-to-width ratio, and time to treatment. Chronic steroid use is also a known risk factor for poor wound healing in wounds of any type. We report the first known case of hyperbaric oxygen therapy and Apligraf, a living bilayer skin substitute, for non-operative salvage of a traumatic degloving injury in 70-year-old female on chronic steroids for sarcoidosis. DECLARATION OF INTEREST: The authors have received no financial support for the material presented in this study outside of the scope of standard patient care reimbursement...
January 2015: Journal of Wound Care
https://www.readbyqxmd.com/read/25424146/a-prospective-randomised-controlled-multi-centre-comparative-effectiveness-study-of-healing-using-dehydrated-human-amnion-chorion-membrane-allograft-bioengineered-skin-substitute-or-standard-of-care-for-treatment-of-chronic-lower-extremity-diabetic-ulcers
#4
RANDOMIZED CONTROLLED TRIAL
Charles M Zelen, Lisa Gould, Thomas E Serena, Marissa J Carter, Jennifer Keller, William W Li
A prospective, randomised, controlled, parallel group, multi-centre clinical trial was conducted at three sites to compare the healing effectiveness of treatment of chronic lower extremity diabetic ulcers with either weekly applications of Apligraf(®) (Organogenesis, Inc., Canton, MA), EpiFix(®) (MiMedx Group, Inc., Marietta, GA), or standard wound care with collagen-alginate dressing. The primary study outcome was the percent change in complete wound healing after 4 and 6 weeks of treatment. Secondary outcomes included percent change in wound area per week, velocity of wound closure and a calculation of the amount and cost of Apligraf or EpiFix used...
December 2015: International Wound Journal
https://www.readbyqxmd.com/read/25192216/selective-case-study-describing-the-use-of-apligraf-on-necrobiosis-lipoidica-associated-with-diabetes
#5
H L Penny, M Faretta, M Rifkah, A Weaver, A Swires, J Spinazzola
Necrobiosis lipoidica is a rare skin disease characterised by large, well-demarcated, symmetrical plaques with overlying telangiectasias and atrophic, fibrotic features. The disease is associated with diabetes mellitus (1 in 300 cases), but can also be linked to other diseases such as rheumatoid arthritis. Women are three times more likely to develop necrobiosis lipoidica compared to men. Ulcerations are the most serious type of complications in necrobiosis lipoidica, and they occur most frequently on the legs of patients...
February 2014: Journal of Wound Care
https://www.readbyqxmd.com/read/24840970/management-of-venous-ulcers
#6
Raghu Kolluri
Chronic venous insufficiency (CVI) results from venous hypertension secondary to superficial or deep venous valvular reflux, as well as venous obstruction. The most severe clinical manifestation of CVI is venous leg ulceration that can result in significant morbidity, including venous gangrene and amputation, albeit rare. Treatment modalities are aimed at reducing venous hypertension. Diuretic therapy, although widely used, only provides short-term improvement of the edema but provides no long-term benefit...
June 2014: Techniques in Vascular and Interventional Radiology
https://www.readbyqxmd.com/read/24600755/selective-case-study-describing-the-use-of-apligraf-on-necrobiosis-lipoidica-associated-with-diabetes
#7
H L Penny, M Faretta, M Rifkah, A Weaver, A Swires, J Spinazzola
Necrobiosis lipoidica is a rare skin disease characterised by large, well-demarcated, symmetrical plaques with overlying telangiectasias and atrophic, fibrotic features. The disease is associated with diabetes mellitus (1 in 300 cases), but can also be linked to other diseases such as rheumatoid arthritis. Women are three times more likely to develop necrobiosis lipoidica compared to men. Ulcerations are the most serious type of complications in necrobiosis lipoidica, and they occur most frequently on the legs of patients...
February 2014: Journal of Wound Care
https://www.readbyqxmd.com/read/24526128/selective-case-study-describing-the-use-of-apligraf-on-necrobiosis-lipoidica-associated-with-diabetes
#8
Hl Penny, M Faretta, M Rifkah, A Weaver, A Swires, J Spinazzola
Necrobiosis lipoidica is a rare skin disease characterised by large, well-demarcated, symmetrical plaques with overlying telangiectasias and atrophic, fibrotic features. The disease is associated with diabetes mellitus (1 in 300 cases), but can also be linked to other diseases such as rheumatoid arthritis. Women are three times more likely to develop necrobiosis lipoidica compared to men. Ulcerations are the most serious type of complications in necrobiosis lipoidica, and they occur most frequently on the legs of patients...
February 2014: Journal of Wound Care
https://www.readbyqxmd.com/read/24028566/late-failure-of-a-split-thickness-skin-graft-in-the-setting-of-homozygous-factor-v-leiden-mutation-a-case-report-and-correlative-animal-model-from-the-wound-etiology-and-healing-we-heal-study
#9
Victoria K Shanmugam, Sean McNish, Joanna Duncan, Brandy Root, Elena Tassi, Anton Wellstein, Bhaskar Kallakury, Christopher E Attinger
We present the case of a 53-year-old Caucasian male smoker with remote history of left lower extremity deep venous thrombosis (DVT) and a strong family history of thrombosis, who presented to the Center for Wound Healing at MedStar Georgetown University Hospital with spontaneous left leg ulceration. Prothrombotic evaluation showed homozygosity for the factor V Leiden (FVL) mutation. Therapeutic anticoagulation was commenced with warfarin (Coumadin®) and the patient underwent successful debridement and Apligraf® followed by split-thickness skin graft (STSG) of two wounds...
October 2015: International Wound Journal
https://www.readbyqxmd.com/read/23086986/stem-cell-therapy-for-critical-limb-ischemia-what-can-we-learn-from-cell-therapy-for-chronic-wounds
#10
REVIEW
Caroline Jadlowiec, Robert A Brenes, Xin Li, Wei Lv, Clinton D Protack, Michael J Collins, Alan Dardik
Although much progress has been made regarding our knowledge of stem cells and their potential applications for therapeutic angiogenesis, there has been less success with the clinical application of this knowledge to patients with critical limb ischemia (CLI). Patients with CLI often have chronic wounds and newer cell-based therapies for chronic wounds show interesting parallels to stem cell therapy for CLI. Several human-derived wound care products and therapies, including human neonatal fibroblast-derived dermis (Dermagraft®), bilayered bioengineered skin substitute (Apligraf®), recombinant human platelet-derived growth factor and autologous platelet-rich plasma may provide insight into the mechanisms through which differentiated cells can be used as therapy for chronic wounds, and, analogously, by which stem cells might function therapeutically in CLI...
October 2012: Vascular
https://www.readbyqxmd.com/read/22663170/clinical-and-cost-efficacy-of-advanced-wound-care-matrices-for-venous-ulcers
#11
REVIEW
Cheryl S Hankin, John Knispel, Maria Lopes, Amy Bronstone, Erik Maus
BACKGROUND: In the United States, venous leg ulcers (VLUs) are commonly associated with substantial disability, impaired quality of life, and high economic costs. Compression therapy, which has remained the standard care for VLUs over several decades, is often insufficient to heal VLUs in a timely manner. VLU-related treatment costs are directly related to time to achieve complete wound closure. Advanced wound care matrices (AWCMs) developed to stimulate wound healing may reduce VLU-related costs associated with delayed healing...
June 2012: Journal of Managed Care Pharmacy: JMCP
https://www.readbyqxmd.com/read/22429013/advances-in-the-topical-treatment-of-diabetic-foot-ulcers
#12
REVIEW
N Papanas, I Eleftheriadou, N Tentolouris, E Maltezos
The diabetic foot remains a major cause of morbidity worldwide. Even though considerable progress has been achieved over the past years, there is still an urgent need for improvement. While established therapeutic modalities (revascularization, casting and debridement) remain the mainstay of management, there is, therefore, continuous development of new treatment options. This review provides an outlook of advances in topical treatment, including bioengineered skin substitutes (such as Dermagraft, Apligraf, HYAFF, OASIS and Graftjacket), extracellular matrix proteins (such as Hyalofill and E-matrix), as well as miscellaneous further therapeutic adjuncts...
May 2012: Current Diabetes Reviews
https://www.readbyqxmd.com/read/22362469/fibroblasts-within-concentrated-collagen-hydrogels-favour-chronic-skin-wound-healing
#13
Christophe Helary, Mylène Zarka, Marie Madeleine Giraud-Guille
Apligraf(®), a skin substitute currently used in skin chronic wound treatment, acts as a source of macromolecules and cytokines to promote wound healing. Normal collagen hydrogel (NCH), obtained from collagen at low concentration (0.66 mg/ml), is the base of the dermal layer. Apligraf has several drawbacks, such as poor persistence of fibroblasts within the normal collagen hydrogel. In the present study we have evaluated concentrated collagen hydrogels at 5 mg/ml (CCH5s) as dermal substitutes for the treatment of skin chronic wounds...
March 2012: Journal of Tissue Engineering and Regenerative Medicine
https://www.readbyqxmd.com/read/22175514/steady-advance-of-stem-cell-therapies-report-from-the-2011-world-stem-cell-summit-pasadena-california-october-3-5
#14
Melanie Swan
Stem cell research and related therapies (including regenerative medicine and cellular therapies) could have a significant near-term impact on worldwide public health and aging. One reason is the industry's strong linkage between policy, science, industry, and patient advocacy, as was clear in the attendance and programming at the 7(th) annual World Stem Cell Summit held in Pasadena, California, October 3-5, 2011. A special conference session sponsored by the SENS Foundation discussed how stem cell therapies are being used to extend healthy life span...
December 2011: Rejuvenation Research
https://www.readbyqxmd.com/read/21913837/a-rapid-fabricated-living-dermal-equivalent-for-skin-tissue-engineering-an-in-vivo-evaluation-in-an-acute-wound-model
#15
Michael Ananta, Robert A Brown, Vivek Mudera
The encapsulation of both cells and a surgical mesh in a polymerizing collagen hydrogel followed by mechanical compression, after polymerization, results in the rapid formation of a living dermal equivalent (LDE) with physical properties suitable for in vivo application. It was found in the current study that the LDE supported the attachment, growth, and differentiation of keratinocytes, allowing for the formation of living skin equivalents (LSEs) with a monolayer epidermis (LSE-M) and a stratified epidermis (LSE-S)...
February 2012: Tissue Engineering. Part A
https://www.readbyqxmd.com/read/21811960/the-evidence-for-the-use-of-growth-factors-and-active-skin-substitutes-for-the-treatment-of-non-infected-diabetic-foot-ulcers-dfu-a-health-technology-assessment-hta
#16
REVIEW
B Buchberger, M Follmann, D Freyer, H Huppertz, A Ehm, J Wasem
AIMS: Assessment of the safety, efficacy and effectiveness of growth factors alone or in combination with other technologies in the treatment of DFU including medical, economical, social, ethical and juridical aspects. METHODS: We systematically searched relevant data bases limited to English and German language and publications since 1990. Review and assessment of the quality of publications followed methods conforming to widely accepted standards for evidence-based medicine and health economics...
September 2011: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/21505282/a-case-of-refractory-pyoderma-gangrenosum-treated-with-a-combination-of-apligraf-and-systemic-immunosuppressive-agents
#17
Giacomo Duchini, Peter Itin, Andreas Arnold
Pyoderma gangrenosum (PG) is a rare inflammatory ulcerative skin disease. A case of refractory PG treated with a combination of immunosuppression and Apligraf (Organogenesis, Canton, Massachusetts) is presented. Under infliximab, systemic corticosteroids, and Apligraf, the wound showed a slow but complete healing. The authors demonstrated the potential benefits of Apligraf in the healing of PG.
May 2011: Advances in Skin & Wound Care
https://www.readbyqxmd.com/read/21360461/-local-treatment-of-chronic-skin-wounds-in-a-swiss-out-patient-wound-centre-2010
#18
REVIEW
Marc Baumgartner, Daniel Tanner, Thomas Hunziker
In Switzerland around 30,000 patients suffer from chronic skin wounds. Appropriate topical wound care along with treatment of the causes of the wounds enables to heal a lot of these patients and to avoid secondary disease such as infections. Thereby, the final goal of wound care is stable reepithelisation. Based on experience with chronic leg ulcers mainly in our out-patient wound centre, we give a survey of the wound dressings we actually use and discuss their wound-phase adapted application. Furthermore, we address the two tissue engineering products reimbursed in Switzerland, Apligraf and EpiDex, as well as the biological matrix product Oasis...
March 2011: Therapeutische Umschau. Revue Thérapeutique
https://www.readbyqxmd.com/read/21326023/retrospective-comparison-of-diabetic-foot-ulcer-and-venous-stasis-ulcer-healing-outcome-between-a-dermal-repair-scaffold-primatrix-and-a-bilayered-living-cell-therapy-apligraf
#19
COMPARATIVE STUDY
Jeffrey C Karr
OBJECTIVE: The goal of this study was to review clinical experience in treating diabetic and venous stasis wounds with Apligraf or PriMatrix. METHODS: A total of 40 diabetic foot ulcers and 28 venous stasis ulcers were treated with either PriMatrix or Apligraf for number of days open and for number of days for complete healing between the 2 treatments. CONCLUSIONS: Although both treatments were highly effective, the study results of 68 ulcers in 48 patients demonstrated that patients treated with PriMatrix healed faster than patients treated with Apligraf despite larger wound sizes...
March 2011: Advances in Skin & Wound Care
https://www.readbyqxmd.com/read/21289885/the-importance-of-growth-factors-for-the-treatment-of-chronic-wounds-in-the-case-of-diabetic-foot-ulcers
#20
Barbara Buchberger, Markus Follmann, Daniela Freyer, Hendrik Huppertz, Alexandra Ehm, Jürgen Wasem
INTRODUCTION: Ulcers as a result of diabetes mellitus are a serious problem with an enormous impact on the overall global disease burden due to the increasing prevalence of diabetes. Because of long hospital stays, rehabilitation, often required home care and the use of social services diabetic foot complications are costly. Therapy with growth factors could be an effective and innovative add-on to standard wound care. RESEARCH QUESTIONS: What is the benefit of therapies with growth factors alone or in combination with other technologies in the treatment of diabetic foot ulcer assessed regarding medical, economical, social, ethical and juridical aspects? METHODS: We systematically searched relevant databases limited to English and German language and publications since 1990...
2010: GMS Health Technology Assessment
keyword
keyword
16609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"